Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silexion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silexion Therapeutics's regulatory disclosures and financial reporting.
Silexion Therapeutics Corp. is a clinical-stage oncology biotech developing RNA interference therapies for KRAS-driven cancers. Lead candidate SIL204, a second-generation siRNA for locally advanced pancreatic cancer, combines intratumoral and subcutaneous dosing with chemotherapy. Regulators in Israel and Germany approved initiation of a Phase 2/3 trial, and the first site in Tel Aviv began operations in late July 2026.
The company plans a best-efforts primary offering of units consisting of ordinary shares or pre-funded warrants, each paired with an ordinary warrant, plus placement agent warrants, and is registering the ordinary shares underlying these instruments. Ordinary shares and publicly traded warrants list on Nasdaq as “SLXN” and “SLXNW”; on August 6, 2026 they closed at $1.79 and $0.020, with 1,349,019 ordinary shares outstanding before the offering.
Silexion is pre-revenue and reported a net loss of $11.9 million in 2025 and $2.7 million for the quarter ended March 31, 2026, with an accumulated deficit of $57.9 million and cash of $2.4 million. Auditors highlighted substantial doubt about its ability to continue as a going concern. The company has relied on multiple reverse share splits, warrant inducement financings, and conversions of a sponsor promissory note originally totaling $3.433 million (reduced to $956 thousand) to restore and maintain Nasdaq listing compliance, and it expects to need substantial additional capital.
Silexion Therapeutics Corp reported new preclinical data for SIL204, an RNAi therapy targeting KRAS-driven cancers. In human pancreatic and non-small cell lung cancer cell lines with KRAS G12D, G12V, and G12C mutations, SIL204 increased expression of the immune death receptor FAS and reduced expression of the immune checkpoint HLA-G, both in a statistically significant, dose-dependent manner.
Together with previously reported MHC-I upregulation in KRAS G12R-mutant pancreatic cells, the findings suggest a coordinated immune-sensitization profile across four KRAS mutations and three immune pathways: antigen presentation, apoptosis sensitivity, and checkpoint reduction. Silexion is advancing SIL204 into Phase 2/3 clinical evaluation, following initiation of its first clinical trial site at Tel Aviv Sourasky Medical Center in July 2026.
Silexion Therapeutics Corp reported changes to its Board and audit committee. Professor Amnon Peled notified the Board of his resignation from the Board and all committees, including the audit committee, effective August 1, 2026. His resignation was for personal reasons and did not result from any disagreement regarding the company’s operations, policies, or practices.
Immediately upon his resignation becoming effective, the Board appointed existing independent director Avner Lushi to the audit committee, filling the vacancy. The Board determined that Lushi meets the independence standards of Nasdaq Listing Rule 5605(c)(2)(A) and SEC Rule 10A-3(b)(1). With his appointment, the audit committee now consists of three independent members—Dror J. Abramov (chair and audit committee financial expert), Ruth Alon, and Lushi—restoring full compliance with Nasdaq’s audit committee composition requirements without using the cure period.
Silexion Therapeutics Corp, a Cayman Islands company with Ordinary Shares and warrants listed on The Nasdaq Stock Market, reported a change in its Board of Directors. On July 30, 2026, Professor Amnon Peled notified the Board of his resignation as a director.
His resignation is for personal reasons and will be effective as of August 1, 2026. The company reports that his decision did not arise from any disagreement with Silexion regarding its operations, policies, or practices.
Silexion Therapeutics Corp. announced the successful initiation of its Phase 2/3 clinical trial of SIL204, a small interfering RNA (siRNA) candidate, in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, formally activating the first clinical site and clearing it to begin patient screening, with first dosing anticipated afterward.
The trial evaluates SIL204 plus standard-of-care chemotherapy using a dual-route strategy that combines intratumoral delivery to overcome stromal barriers with systemic administration to address metastatic disease. It begins with an initial safety run-in of approximately 18 patients, then expands globally to a randomized cohort of approximately 166 patients. SIL204 is designed to silence a broad range of KRAS mutations, which occur in about 90% of pancreatic cancers, 45% of colorectal cancers, and 30–35% of lung adenocarcinomas, supporting potential use across multiple KRAS-driven tumors.
Silexion Therapeutics Corp reported that at its reconvened extraordinary general meeting on July 20, 2026, shareholders approved changes affecting warrants and share capital. The meeting initially lacked a standard quorum, but under the company’s articles, shareholders present after a half hour constituted a valid quorum.
Holders of 230,276 ordinary shares, representing 21.7% of issued and outstanding ordinary shares, were present in person or by proxy. A New Warrant Exercisability Proposal passed with 214,091 votes (93.3%) in favor and 15,293 against. An Authorized Share Capital Increase Proposal passed with 205,551 votes (89.8%) in favor and 23,382 against. The associated Memorandum Amendment, which increases authorized share capital, became effective when filed in the Cayman Islands on July 21, 2026.
Silexion Therapeutics Corp’s major holder has updated its ownership report. Moringa Sponsor, Moringa Partners Ltd and Ilan Levin together report beneficial ownership of 199,053 ordinary shares, representing 10.6% of Silexion’s ordinary shares, based on 1,877,696 shares outstanding as disclosed in a Form S‑3.
The filing details share issuances of 45,000, 92,500 and 60,819 ordinary shares that Silexion reported as issued to Moringa Sponsor upon conversion of an Amended and Restated Promissory Note originally totaling $3.4 million, including conversions of $1.8 million and two tranches of $0.4 million each. The reporting persons state they dispute the validity of these particular share issuances and do not concede beneficial ownership of those shares, and they characterize this amendment as being filed out of an abundance of caution.
Silexion Therapeutics Corp is calling an extraordinary general meeting on July 13, 2026 to seek shareholder approval for two capital-related proposals tied to its Nasdaq listing and clinical funding needs.
The first proposal asks shareholders to approve the exercisability of 399,020 new Series C and D warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share that were issued in a May 18, 2026 warrant inducement financing which raised about $1.0 million and helped restore compliance with Nasdaq’s $2.5 million shareholders’ equity requirement.
The second proposal would increase authorized share capital by 10,000,000 ordinary shares to a total of 15,900,000 shares, giving Silexion more capacity to issue equity for financings, operations and potential business development while maintaining its Nasdaq Capital Market listing as it begins Phase 2/3 trials for SIL‑204.
Silexion Therapeutics Corp files a shelf registration to register the resale by selling shareholders of up to 859,609 ordinary shares, comprising up to 399,020 shares issuable upon new warrants, 13,966 placement agent warrant shares and up to 446,623 shares issuable upon conversion of the Sponsor Promissory Note.
The prospectus states the company will receive no proceeds from sales by the selling shareholders, though it may receive cash proceeds if warrants are exercised for cash. The filing discloses recent financings (an inducement warrant exercise raising ~$1.0M, ATM sales of ~$1.75M net aggregate through June 10, 2026), a 1-for-10 reverse split in May 2026, restored Nasdaq shareholders' equity compliance above the $2.5M minimum, and ongoing Nasdaq monitoring until September 23, 2026.
Silexion Therapeutics Corp reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares via fully vested restricted share units, settled immediately in respect of his services as an officer and approved by the board of directors. Following this grant, he directly holds 8,789 Ordinary Shares.
The filing also updates option holdings after a 1-for-10 reverse share split effective on May 28, 2026. Mitchell now holds options to purchase 48 Ordinary Shares at an exercise price of $9,077.10 per share, expiring on June 7, 2032.